These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 12889158)

  • 1. [Progress in the studies on the CYP2C19 polymorphism].
    He N; Zhou HH
    Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):171-4. PubMed ID: 12889158
    [No Abstract]   [Full Text] [Related]  

  • 2. Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population.
    Itoh K; Inoue K; Nakao H; Yanagiwara S; Tada H; Suzuki T
    Anal Biochem; 2000 Aug; 284(1):160-2. PubMed ID: 10933870
    [No Abstract]   [Full Text] [Related]  

  • 3. Misclassification of allele CYP2C19*10 as CY2C19*2 by a commonly used PCR-RFLP procedure.
    Rasmussen H; Werge T
    Genet Test; 2008 Mar; 12(1):57-8. PubMed ID: 18373404
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.
    Ohkubo Y; Ueta A; Ando N; Ito T; Yamaguchi S; Mizuno K; Sumi S; Maeda T; Yamazaki D; Kurono Y; Fujimoto S; Togari H
    J Hum Genet; 2006; 51(2):118-123. PubMed ID: 16307177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allele and genotype frequency of CYP2C19 in a Tamilian population.
    Adithan C; Gerard N; Vasu S; Rosemary J; Shashindran CH; Krishnamoorthy R
    Br J Clin Pharmacol; 2003 Sep; 56(3):331-3. PubMed ID: 12919183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system.
    Matsumoto N; Kakihara F; Kimura S; Kurebayashi Y; Hirai M; Yohda M; Hasegawa S
    Anal Biochem; 2007 Nov; 370(1):121-3. PubMed ID: 17603002
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
    Burger DM; Schwietert HR; Colbers EP; Becker M
    Br J Clin Pharmacol; 2006 Aug; 62(2):250-2. PubMed ID: 16842404
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between CYP2A6 and CYP2C19 mutant alleles.
    Lam K; Chow L; Leung T; Wing YK; Chiu HF; Garcia-Barceló M
    Clin Pharmacol Ther; 1999 Dec; 66(6):647. PubMed ID: 10613622
    [No Abstract]   [Full Text] [Related]  

  • 9. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
    Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
    Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population].
    Fu LQ; Huang F; Wu DZ; Guo JH
    Yao Xue Xue Bao; 2004 Mar; 39(3):161-3. PubMed ID: 15171646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population.
    Kubota T; Hibi N; Chiba K
    Biochem Pharmacol; 1998 Jun; 55(12):2039-42. PubMed ID: 9714325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
    Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose of proton pump inhibitors and the CYP2C19 genotype.
    Bertilsson L
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):1. PubMed ID: 15245568
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection of CYP2C19 alleles *1, *2 and *3 by multiplex polymerase chain reaction.
    Griese EU; Läpple F; Eichelbaum M
    Pharmacogenetics; 1999 Jun; 9(3):389-91. PubMed ID: 10471071
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxylation of lansoprazole in poor metabolizers of CYP2C19.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A
    Br J Clin Pharmacol; 2006 Mar; 61(3):361; author reply 361-2. PubMed ID: 16487234
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study.
    Luo HR; Poland RE; Lin KM; Wan YJ
    Clin Pharmacol Ther; 2006 Jul; 80(1):33-40. PubMed ID: 16815315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Chen MC; Hu CT; Wang LY; Lin HH
    Aliment Pharmacol Ther; 2005 Aug; 22(3):274-5; author reply 275-6. PubMed ID: 16091067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.